Felicia Zhang Perkins

Felicia Zhang Perkins

Auto-generated profile, based on publicly available information

Felicia Zhang Perkins

Department of Surgery, Washington University School of Medicine, Saint Louis, MO, USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2026 in Science Advances
Verified
Journal Article
Closed access
FPFelicia Zhang Perkins
Felicia Zhang Perkins
XZXiuli Zhang
Xiuli Zhang
YYYik Yeung Lawrence Yu
Yik Yeung Lawrence Yu
YYYilin Yang
Yilin Yang
DCDarren Cullinan
Darren Cullinan
WGWilliam E. Gillanders
William E. Gillanders
Pancreatic ductal adenocarcinoma (PDAC) is unresponsive to standard immunotherapies despite harboring cancer neoantigens capable of eliciting T cell responses. We completed two phase 1 clinical trials (NCT03956056 and NCT03122106) evaluating safety and immunogenicity of synthetic long peptide (SLP) and DNA personalized cancer vaccines (PCVs). PCVs were administered after resection and adjuvant chemotherapy. Tumor/normal whole-exome sequencing, RNA sequencing, and pVACtools were used to identify and prioritize candidate PCV neoantigens. PCVs were well tolerated without any grade ≥3 adverse events. Neoantigen-specific responses were demonstrated by interferon-γ enzyme-linked immunospot and intracellular cytokine staining. Expanded T cell receptor clonotypes were sequenced and transduced into autologous peripheral blood mononuclear cells to confirm neoantigen specificity. When compared with a contemporaneous institutional propensity-matched cohort, PCV patients demonstrated a trend toward prolonged median overall survival (4.4 versus 3.5 years, log-rank P = 0.23). Overall, PDAC PCVs are safe and feasible and elicit polyclonal T cell responses, linking prioritized cancer neoantigens to functional antitumor immunity.